<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34219295</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis with speech apraxia, predominant upper motor neuron signs, and prominent iron accumulation in the frontal operculum and precentral gyrus.</ArticleTitle><Pagination><StartPage>324</StartPage><EndPage>331</EndPage><MedlinePgn>324-331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12763</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease; transactivation response DNA-binding protein of 43&#x2009;kDa (TDP-43) and iron accumulation are supposed to play a crucial role in the pathomechanism of the disease. Here, we report an unusual case of a patient with ALS who presented with speech apraxia as an initial symptom and upper motor neuron deficiencies. In the early clinical stages, single-photon emission computed tomography visualized focal hypoperfusion of the right frontal operculum, and magnetic resonance imaging identified a hypointense area along the frontal lobe on T2-weighted images. Neuropathological examination revealed that neuronophagia of Betz cells, gliosis, appearance of phosphorylated TDP-43 (p-TDP-43)-positive glial and neuronal inclusions, and prominent iron accumulation were frequently visible in the precentral gyrus. TDP-43 pathology and focal iron accumulation were also visible in the frontal operculum, but only a mild neuronal loss and a few p-TDP-43-positive neuronal and glial inclusions were found in the hypoglossal nucleus of the medulla oblongata and anterior horn of the spinal cord. Immunoblot analysis revealed an atypical band pattern for ALS. In our case, abnormal TDP-43 and iron accumulation might possibly have caused neurodegeneration of the frontal operculum, in tandem or independently; it might then have spread into the primary motor area. Our results suggest a causative association between TDP-43 and iron accumulation in the pathomechanisms of ALS presenting with upper motor neuron signs.</AbstractText><CopyrightInformation>&#xa9; 2021 Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitani</LastName><ForeName>Tomoki T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Goichi</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8890-2743</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kido</LastName><ForeName>Kansuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Rika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yonenobu</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeki</LastName><ForeName>Chizu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuno</LastName><ForeName>Tatsusada</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morii</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7415-8159</Identifier><AffiliationInfo><Affiliation>Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9709-5242</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorders, Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochizuki</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20K06910</GrantID><Agency>Japan Society for the Promotion of Science Grants in Aid for Scientific Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001072" MajorTopicYN="Y">Apraxias</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="Y">Motor Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">iron</Keyword><Keyword MajorTopicYN="N">precentral gyrus</Keyword><Keyword MajorTopicYN="N">speech apraxia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>5</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34219295</ArticleId><ArticleId IdType="doi">10.1111/neup.12763</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.</Citation></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-611.</Citation></Reference><Reference><Citation>Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm (Vienna) 2011; 118: 473-477.</Citation></Reference><Reference><Citation>Joppe K, Roser AE, Maass F, Lingor P. The contribution of iron to protein aggregation disorders in the central nervous system. Front Neurosci 2019; 13: 15.</Citation></Reference><Reference><Citation>Kwan JY, Jeong SY, Van Gelderen P et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: Correlating 7 tesla MRI and pathology. PLoS One 2012; 7: e35241.</Citation></Reference><Reference><Citation>Ignjatovi&#x107; A, Stevi&#x107; Z, Lavrni&#x107; S, Dakovi&#x107; M, Ba&#x10d;i&#x107; G. Brain iron MRI: A biomarker for amyotrophic lateral sclerosis. J Magn Reson Imaging 2013; 38: 1472-1479.</Citation></Reference><Reference><Citation>Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: A preliminary study. J Neurol Sci 1995; 130: 203-208.</Citation></Reference><Reference><Citation>Veyrat-Durebex C, Corcia P, Mucha A et al. Iron metabolism disturbance in a French cohort of ALS patients. Biomed Res Int 2014; 2014: 485723.</Citation></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: A cross-sectional study. Intern Med 2012; 51: 1501-1508.</Citation></Reference><Reference><Citation>Nadjar Y, Gordon P, Corcia P et al. Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One 2012; 7: e45034.</Citation></Reference><Reference><Citation>De Reuck JL, Deramecourt V, Auger F et al. Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: A semi-quantitative 7.0 T magnetic resonance imaging study. Eur J Neurol 2014; 21: 1026-1031.</Citation></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008; 64: 60-70.</Citation></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20-38.</Citation></Reference><Reference><Citation>Maeda K, Ogawa N, Idehara R, Shiraishi T, Tatsumi H. Amyotrophic lateral sclerosis presenting with apraxia of speech. J Neurol 2013; 260: 1667-1669.</Citation></Reference><Reference><Citation>Lee DJ, Bigio EH, Rogalski EJ, Mesulam MM. Speech and language presentations of FTLD-TDP type B neuropathology. J Neuropathol Exp Neurol 2020; 79: 277-283.</Citation></Reference><Reference><Citation>Poole ML, Brodtmann A, Darby D, Vogel AP. Motor speech phenotypes of frontotemporal dementia, primary progressive aphasia, and progressive apraxia of speech. J Speech Lang Hear Res 2017; 60: 897-911.</Citation></Reference><Reference><Citation>Keller SS, Roberts N, Hopkins W. A comparative magnetic resonance imaging study of the anatomy, variability, and asymmetry of Broca's area in the human and chimpanzee brain. J Neurosci 2009; 29: 14607-14616.</Citation></Reference><Reference><Citation>Kawamura M, Ishihara K. Primary progressive &#x201c;anarthria/apraxia of speech (AOS)&#x201d;. High Brain Funct Res 2012; 32: 385-392. (in Japanese with English abstract.).</Citation></Reference><Reference><Citation>Dronkers NF. A new brain region for coordinating speech articulation. Nature 1996; 384: 159-161.</Citation></Reference><Reference><Citation>Ishikawa K, Nagura H, Yokota T, Yamanouchi H. Signal loss in the motor cortex on magnetic resonance images in amyotrophic lateral sclerosis. Ann Neurol 1993; 33: 218-222.</Citation></Reference><Reference><Citation>Ramos P, Santos A, Pinto NR, Mendes R, Magalh&#xe3;es T, Almeida A. Iron levels in the human brain: A post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 2014; 28: 13-17.</Citation></Reference><Reference><Citation>Nagano S, Jinno J, Abdelhamid RF et al. TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol 2020; 140: 695-713.</Citation></Reference><Reference><Citation>Haraguchi T, Terada S, Ishizu H et al. Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome). Neuropathology 2011; 31: 531-539.</Citation></Reference><Reference><Citation>Cohen TJ, Hwang AW, Unger T, Trojanowski JQ, Lee VM. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J 2012; 31: 1241-1252.</Citation></Reference><Reference><Citation>Tsuji H, Arai T, Kametani F et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 2012; 135: 3380-3391.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>